166 related articles for article (PubMed ID: 16046545)
1. Jade-1, a candidate renal tumor suppressor that promotes apoptosis.
Zhou MI; Foy RL; Chitalia VC; Zhao J; Panchenko MV; Wang H; Cohen HT
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):11035-40. PubMed ID: 16046545
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent.
Zhou MI; Wang H; Foy RL; Ross JJ; Cohen HT
Cancer Res; 2004 Feb; 64(4):1278-86. PubMed ID: 14973063
[TBL] [Abstract][Full Text] [Related]
3. Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
Zeng L; Bai M; Mittal AK; El-Jouni W; Zhou J; Cohen DM; Zhou MI; Cohen HT
Cancer Res; 2013 Sep; 73(17):5371-80. PubMed ID: 23824745
[TBL] [Abstract][Full Text] [Related]
4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
5. The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1.
Zhou MI; Wang H; Ross JJ; Kuzmin I; Xu C; Cohen HT
J Biol Chem; 2002 Oct; 277(42):39887-98. PubMed ID: 12169691
[TBL] [Abstract][Full Text] [Related]
6. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
8. Polycystin-1 regulates the stability and ubiquitination of transcription factor Jade-1.
Foy RL; Chitalia VC; Panchenko MV; Zeng L; Lopez D; Lee JW; Rana SV; Boletta A; Qian F; Tsiokas L; Piontek KB; Germino GG; Zhou MI; Cohen HT
Hum Mol Genet; 2012 Dec; 21(26):5456-71. PubMed ID: 23001567
[TBL] [Abstract][Full Text] [Related]
9. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
Nyhan MJ; O'Sullivan GC; McKenna SL
Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
11. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau partner Jade-1 is a transcriptional co-activator associated with histone acetyltransferase activity.
Panchenko MV; Zhou MI; Cohen HT
J Biol Chem; 2004 Dec; 279(53):56032-41. PubMed ID: 15502158
[TBL] [Abstract][Full Text] [Related]
13. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha.
Sun X; Kanwar JR; Leung E; Vale M; Krissansen GW
Gene Ther; 2003 Dec; 10(25):2081-9. PubMed ID: 14595381
[TBL] [Abstract][Full Text] [Related]
14. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
15. Role of VHL gene mutation in human cancer.
Kim WY; Kaelin WG
J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
[TBL] [Abstract][Full Text] [Related]
16. von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility.
Kamada M; Suzuki K; Kato Y; Okuda H; Shuin T
Cancer Res; 2001 May; 61(10):4184-9. PubMed ID: 11358843
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
Zimmer M; Doucette D; Siddiqui N; Iliopoulos O
Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465
[TBL] [Abstract][Full Text] [Related]
18. Jade-1: its structure, regulation and functions in the renal cancer.
Zhang YC; Du WQ; Zhang RY; Zheng JN; Pei DS
Curr Mol Med; 2016; 16(1):63-9. PubMed ID: 26695694
[TBL] [Abstract][Full Text] [Related]
19. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion.
Datta K; Sundberg C; Karumanchi SA; Mukhopadhyay D
Cancer Res; 2001 Mar; 61(5):1768-75. PubMed ID: 11280720
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
